Loading...
Market
Story
Scholar Rock's Apitegromab Succeeds in Phase 3 SMA Trial with p=0.019, Stock Soars 200%
Oct 7, 2024, 12:01 PM
Scholar Rock announced that its drug apitegromab met the primary endpoint in a Phase 3 SAPPHIRE study for treating spinal muscular atrophy (SMA). The trial, which achieved statistical significance with a p-value of 0.019, demonstrated a clinically meaningful improvement in motor function among patients. As a result, Scholar Rock's stock soared more than 200%. The late-stage study involved patients already on standard-of-care treatments such as Spinraza and Risdiplam. The success of the trial positions Scholar Rock as a potential key player in the SMA treatment market.
View original story
Similar markets
Europe • 25%
Asia • 25%
South America • 25%
Other • 25%
Yes • 50%
No • 50%
Approved in the US only • 25%
Approved in the US and EU • 25%
Approved in the US, EU, and other major markets • 25%
Not approved in any major market • 25%
Below $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Above $1 billion • 25%
SMA Type 3 • 25%
SMA Type 2 • 25%
Both SMA Type 2 and 3 • 25%
Other • 25%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
